Vascular Invasion Predicts Recurrence in Stage IA2-IB Lung Adenocarcinoma but not Squamous Cell Carcinoma

被引:3
|
作者
Suaiti, Lubna [1 ]
Sullivan, Travis B. [2 ]
Rieger-Christ, Kimberly M. [2 ]
Servais, Elliot L. [3 ]
Suzuki, Kei [4 ,6 ]
Burks, Eric J. [1 ,2 ,5 ]
机构
[1] Boston Univ, Boston Med Ctr, Dept Pathol & Lab Med, Sch Med, Boston, MA USA
[2] Lahey Hosp & Med Ctr, Dept Translat Res, Ian C Summerhayes Cell & Mol Biol Lab, Burlington, MA USA
[3] Lahey Hosp & Med Ctr, Dept Surg, Burlington, MA USA
[4] Boston Univ, Boston Med Ctr, Dept Surg, Sch Med, Boston, MA USA
[5] Boston Univ Mallory Pathol Associates, Dept Pathol & Labora tory Med, 670 Albany St,Suite 304, Boston, MA 02118 USA
[6] INOVA, Dept Surg, Div Thorac Surg, Falls Church, VA USA
关键词
Lymphovascular; AJCC; NCCN; Pathology; Adjuvant; LYMPHOVASCULAR INVASION; PROGNOSTIC IMPACT; VESSEL INVASION; MICROVASCULAR INVASION; LYMPHATIC INVASION; NUCLEAR-DIAMETER; PRIMARY TUMOR; BLOOD-VESSEL; CANCER; INDICATOR;
D O I
10.1016/j.cllc.2022.12.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
NCCN-guidelines list vascular invasion (VI) as a risk-factor warranting consideration of adjuvant therapy among stage IB NSCLC. Among resected stage IA2-IB LUAD (n =344) and LUSC (n =102), VI predicted worse 5-year RFS for LUAD (64% vs. 90%, P <0.001) but not LUSC (83% vs. 80%, P =0.852). Guidelines should be modified to specify VI as a risk-factor only for stage I adenocarcinoma. Background: Lymphovascular invasion (LVI) is an adverse prognostic feature in resected stage I non-small cell lung cancer (NSCLC); however, it is unclear if the prognostic significance applies to both lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC). Materials and Methods: A retrospective review of H&E-stained slides from surgically resected AJCC 8th ed. stage IA2-IB LUAD (n = 344) and LUSC (n = 102) from two institutions was performed. LVI was defined as either lymphatic (LI) or vascular (VI) invasion. Outcomes were assessed by 5-year recurrence-free survival (RFS) estimates using the Kaplan-Meier method. Results: The cohorts of LUAD and LUSC showed no significant differences in 5-year RFS (81% each), stage, age, race, or surgical procedure. The presence of LVI, VI, and LI was predictive of 5-year RFS for LUAD (LVI + 71% vs. LVI -92%, P < 0.001; VI + 64% vs. VI -90%, P < 0.001; LI + 75% vs. LI -84%, P = 0.030) but not LUSC (LVI + 84% vs. LVI -79%, P = 0.740; VI + 83% vs. VI-80%, P = 0.852; LI + 84% vs. LI -81%, P = 0.757). Among LUAD with LVI, VI was a stronger predictor of 5-year RFS than the remaining subset of VI-LI + tumors (64% vs. 87%, P = 004). Subset analysis of LI among LUAD stratified by VI showed no significant prognostic advantage to adding LI for risk stratification (VI-LI + 87% vs. VI-LI -92%, P = 0.347 & VI + LI + 62% vs. VI + LI-66%, P = 0.422). VI was present in 36% of LUAD. Conclusion: Vascular invasion is a strong predictor of recurrence in stage IA2-IB LUAD but not in LUSC. Adjuvant therapy trials should be directed at this subgroup.
引用
收藏
页码:E126 / E133
页数:8
相关论文
共 50 条
  • [41] Risk grouping in stage IB squamous cell cervical carcinoma
    van de Putte, G
    Lie, AK
    Vach, W
    Baekelandt, M
    Kristensen, GB
    GYNECOLOGIC ONCOLOGY, 2005, 99 (01) : 106 - 112
  • [42] Prediction models for recurrence and survival following surgery in stage IA and IB non-small cell lung cancer
    Ost, David E.
    CHEST, 2006, 130 (04) : 102S - 102S
  • [43] Prognostic impact of lymphatic invasion for pathological stage I squamous cell carcinoma of the lung
    Tsutani Y.
    Miyata Y.
    Mimura T.
    Kushitani K.
    Takeshima Y.
    Yoshimura M.
    Okada M.
    General Thoracic and Cardiovascular Surgery, 2015, 63 (3) : 153 - 158
  • [44] DISCUSSION OF STAGE IA SQUAMOUS CELL CARCINOMA OF UTERINE CERVIX
    WILDS, PL
    FOX, CH
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1969, 105 (01) : 55 - &
  • [45] Micropapillary or solid pattern predicts recurrence free survival benefit from adjuvant chemotherapy in patients with stage IB lung adenocarcinoma
    Ma, Minjie
    She, Yunlang
    Ren, Yijiu
    Dai, Chenyang
    Zhang, Lei
    Xie, Huikang
    Wu, Chunyan
    Yang, Minglei
    Xie, Dong
    Chen, Chang
    JOURNAL OF THORACIC DISEASE, 2018, 10 (09) : 5384 - +
  • [46] Machine learning-based histological classification that predicts recurrence of lung squamous cell carcinoma
    Koike, Yutaro
    Aokage, Keiju
    Ikeda, Kosuke
    Nakai, Tokiko
    Tane, Kenta
    Miyoshi, Tomohiro
    Sugano, Masato
    Kojima, Motohiro
    Fujii, Satoshi
    Kuwata, Takeshi
    Ochiai, Atsushi
    Tanaka, Toshiyuki
    Suzuki, Kenji
    Tsuboi, Masahiro
    Ishii, Genichiro
    CANCER SCIENCE, 2021, 112 : 882 - 882
  • [47] Saving time is saving lives: a delayed lobectomy predicts poorer overall survival in patients with clinical stage IA squamous cell carcinoma of the lung
    Wu, Ching Feng
    Chao, Yin-Kai
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S3147 - S3148
  • [48] LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma
    Liu, Bing
    Chen, Yifei
    Yang, Jiong
    ONCOTARGET, 2017, 8 (15) : 24275 - 24291
  • [49] Prognostic significance of synaptophysin in stage of squamous carcinoma and adenocarcinoma of the lung
    Gonzaiez-Aragoneses, Federico
    Moreno-Mata, Nicolas
    Cebollero-Presmanes, Maria
    Garcia-Yuste, Mariano
    Canizares-Carretero, Miguel Angel
    Molins-Lopez-Rodo, Laureano
    Quevedo-Losada, Santiago
    Torres-Lanzas, Juan
    Alvarez-Fernandez, Emilio
    CANCER, 2007, 110 (08) : 1776 - 1781
  • [50] A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA
    Lee, Yoo-Young
    Choi, Chel Hun
    Kim, Tae-Joong
    Lee, Jeong-Won
    Kim, Byoung-Gie
    Lee, Je-Ho
    Bae, Duk-Soo
    GYNECOLOGIC ONCOLOGY, 2011, 120 (03) : 439 - 443